ሌንቫቲኒብ (ሌንቪማ)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of ታይሮይድ ካንሰር.
ኢሳይ እንዳሉት ሌኒቪማ የማይለቀቅ የታይሮይድ ካንሰር ክሊኒካዊ ሕክምና አዲሱ መስፈርት ይሆናል። ኢንዱስትሪው ስለ ሌንቪማ በጣም ተስፋ ሰጭ ነው ፣ እናም መድሃኒቱ ለኢሳኢ አዲስ የገንዘብ ላም እንደሚሆን ይጠበቃል ፣ ዓመታዊ የሽያጭ ከፍተኛው ከ 1 ቢሊዮን ዶላር በላይ ነው።
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved እብጠት volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
በአሁኑ ጊዜ ምንም እንኳን አብዛኛዎቹ የታይሮይድ ካንሰር ዓይነቶች ሊታከሙ ቢችሉም, እየባሰ ከሄደ በኋላ ለህክምና የሚሆን ጥቂት አማራጮች አሉ. ልዩነት የታይሮይድ ካንሰር (DTC) በጣም የተለመደ አደገኛ የታይሮይድ ዕጢ ነው, እና በቅርብ ዓመታት ውስጥ የመከሰቱ አጋጣሚ ከጊዜ ወደ ጊዜ እየጨመረ መጥቷል.
Lenvatinib የቃል ባለብዙ ተቀባይ ታይሮሲን ኪናሴ (RTK) አጋቾቹ ልብ ወለድ አስገዳጅ ሁኔታ ያለው ነው። በእብጠት መስፋፋት እና ኦንኮጅኒክ ምልክት ማድረጊያ መንገዶች ላይ የተሳተፉ ሌሎች RTK ዎችን ከመከልከል በተጨማሪ የቫስኩላር endothelial growth factor (VEGF) ተቀባይ ኪናሴ እንቅስቃሴን መርጦ ሊገታ ይችላል።
